Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D9LA6Q
|
|||
| Drug Name |
COM902
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [1] | |
| Company |
Compugen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | V-set and immunoglobulin domain-containing protein 9 (TIGIT) | Target Info | . | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04354246) COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. Cancer Immunol Immunother. 2021 Apr 26. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.